Document Detail

Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues.
MedLine Citation:
PMID:  17961169     Owner:  NLM     Status:  MEDLINE    
Bypassing therapy is usually necessary to control or prevent bleeding episodes in patients with haemophilia A or B and high-titre inhibitors. Factor VIII inhibitor bypassing activity (FEIBA) has a long history of successful use in the acute, surgical and prophylactic treatment settings, but safety concerns have made some reluctant to administer this bypassing agent. A review of the literature and clinical trial data show that FEIBA has a low prevalence of thrombosis, a low prevalence of anamnesis that does not impact haemostatic efficacy and an excellent record of pathogen safety and clinical tolerability.
L M Aledort
Related Documents :
1081529 - Storage of polyvinylpyrrolidone mimicking a congenital mucolipid storage disease in a p...
9622209 - Clinical experience with recombinant factor viia.
10679799 - Activated recombinant human coagulation factor vii (rfviia) therapy for abdominal bleed...
1348999 - Management of massive upper gastrointestinal haemorrhage from multiple sites of peptic ...
18228649 - Bleeding complications in acute coronary syndromes and percutaneous coronary interventi...
14529929 - Rapid correction of prothrombin time after low-dose recombinant factor viia in patients...
25280089 - Prognostic value of intrathecal heme oxygenase-1 concentration in patients with fisher ...
21696569 - Safety and efficacy of radiation therapy as secondary prophylaxis for heterotopic ossif...
10460909 - Colonoscopy in octogenarians: a review of 428 cases.
Publication Detail:
Type:  Journal Article; Review     Date:  2007-10-22
Journal Detail:
Title:  Haemophilia : the official journal of the World Federation of Hemophilia     Volume:  14     ISSN:  1365-2516     ISO Abbreviation:  Haemophilia     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2008-01-10     Completed Date:  2008-04-07     Revised Date:  2009-10-21    
Medline Journal Info:
Nlm Unique ID:  9442916     Medline TA:  Haemophilia     Country:  England    
Other Details:
Languages:  eng     Pagination:  39-43     Citation Subset:  IM    
Mount Sinai School of Medicine, New York, NY 10029, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Coagulation Factors / adverse effects,  therapeutic use*
Hemophilia A / complications,  drug therapy*,  immunology
Hemorrhage / prevention & control
Thrombosis / chemically induced
Reg. No./Substance:
0/Antibodies; 0/Blood Coagulation Factors; 78690-39-8/Feiba

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Review of quality of life: menorrhagia in women with or without inherited bleeding disorders.
Next Document:  Kwoniella mangroviensis gen. nov., sp.nov. (Tremellales, Basidiomycota), a teleomorphic yeast from m...